bullish

Pharmaron Beijing Co Ltd-H

Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec

The insight analyzed Pharmaron from a different angle after it released the 2021Q3 results,which included the key bottleneck and concerns in terms of the business outlook if compared with Wuxi AppTec.

Equity Bottom-Up
98 Views, 28 Oct 2021 09:50
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns
    11 Nov 2021
  • Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance
    09 Nov 2021
  • Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO
    08 Nov 2021
  • Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec
    28 Oct 2021
  • WuXi AppTec (603259.CH/2359.HK) - The Smart Business Model
    21 Sep 2021
  • Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough
    19 Aug 2021
  • Pre-IPO Ambio Pharmaceuticals - The Particularity of Peptide Drugs, the Strength and the Concerns
    12 Aug 2021
  • WuXi Biologics (2269 HK) - The Strength and the Potential Risk
    01 Apr 2021
x